Dr. Lasky is an expert in biotechnology, a field that he has worked in commercially for over 33 years. In 1981, he was a founding scientist of Genetics Institute (acquired by Wyeth), one of the earliest biotechnology companies. Prior to joining USVP, Dr. Lasky was a scientist at Genentech for 20 years where he worked in various disciplines including vaccinology, immunology, stem cell biology, cellular signaling mechanisms, and monoclonal antibody therapy of tumors. Two of the vaccines that he worked on, for herpes simplex virus and HIV infection, entered Phase III clinical trials.
He is a coauthor on 138 publications and a co-inventor on 38 issued and pending patents, several of which generate significant (9 figure) licensing royalties for Genentech. He was a standing member of the Research Review Committee that directed research across all product development areas at Genentech. Dr. Lasky attained the company's highest scientific position, Genentech Fellow (there were only three research Genentech Fellows in the company’s history), before he retired in 2002. Dr. Lasky has also served on numerous NCI and NIH scientific review panels and has reviewed hundreds of papers for many prestigious journals.
Dr. Lasky joined USVP in 2007 and was the founding investor of Cleave Pharmaceuticals and eFFector Pharmaceuticals and was an investor in Intellikine Pharmaceuticals (acquired by Millenium/Takeda). As a general partner of Latterell Venture Partners from 2002 to 2007, Dr. Lasky was the founding investor of Proteolix (acquired by Onyx Pharmaceuticals), OncoMed (NASDAQ: OMED) and was instrumental in the founding of Cellective Pharmaceuticals (acquired by Medimmune). Proteolix, the company that he started in 2003, received accelerated approval for their drug, Carfilzomib/Kyprolis, for the treatment of multiple myeloma in 2012.
Dr. Lasky holds BA and PhD degrees in molecular biology from UCLA and completed his post-doctoral studies at The California Institute of Technology.